Iongen Therapeutics raised over 100 million RMB in a Pre-A financing round led by Qiming Venture Partners to develop innovative non-opioid pain therapies targeting the Nav1.8 sodium channel.
Target Company Overview
Iongen Therapeutics Co., Ltd. is a biotechnology firm that specializes in the development of non-opioid pain medications. By focusing on innovative approaches, the company seeks to deliver best-in-class solutions to address the global pain management crisis. Recently, Iongen Therapeutics completed its Pre-A financing round, raising over 100 million RMB to advance its research and development efforts.
The funding garnered is earmarked for the preclinical and early clinical development of a promising management portfolio, particularly targeting the Nav1.8 sodium channel with a novel small-molecule drug. This strategic focus underscores Iongen’s commitment to providing alternative pain management options free from opioid-related risks.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The biotechnology industry in China has witnessed significant growth in recent years, propelled by advancements in research and development, increased funding from various sources, and supportive government
Similar Deals
Qiming Venture Partners
invested in
Iongen Therapeutics Co., Ltd.
in 2025
in a Pre-Seed Stage deal
Disclosed details
Transaction Size: $14M